Perry P J, Pfohl B M, Kelly M W
Division of Clinical Pharmacy, College of Pharmacy, University of Iowa, Iowa City 52242.
J Clin Psychopharmacol. 1988 Feb;8(1):38-43.
Data from pharmacokinetics studies that examined the relationship of haloperidol serum concentrations and therapeutic response in schizophrenic patients were reexamined utilizing the method of logistic regression analysis. A linear rather than a curvilinear relationship was obvious between serum haloperidol concentration and therapeutic response according to both the regression analysis and inspection of the distribution of the data. It was concluded that a serum haloperidol concentration in the range of 9 to 15 ng/ml was associated with a 30% decrease in the total Brief Psychiatric Rating Scale (BPRS) score. Haloperidol concentrations above these appear unlikely in the majority of patients to produce any additional reduction of symptoms. The BPRS psychosis factor finding suggested an analogous finding for serum haloperidol concentrations between 12 and 17 ng/ml. The analyses suggest that the probability of response to haloperidol seems to reach a point of diminishing return at concentrations of approximately 9 to 17 ng/ml. Serum concentrations above this limit do not appear to either decrease or increase the probability of response.
利用逻辑回归分析方法,重新审视了药代动力学研究的数据,这些研究考察了精神分裂症患者中氟哌啶醇血清浓度与治疗反应之间的关系。根据回归分析以及对数据分布的检查,血清氟哌啶醇浓度与治疗反应之间呈现出线性而非曲线关系。得出的结论是,血清氟哌啶醇浓度在9至15纳克/毫升范围内与简明精神病评定量表(BPRS)总分降低30%相关。在大多数患者中,高于这些浓度的氟哌啶醇似乎不太可能使症状进一步减轻。BPRS精神病因子的研究结果表明,血清氟哌啶醇浓度在12至17纳克/毫升之间也有类似的发现。分析表明,在浓度约为9至17纳克/毫升时,对氟哌啶醇产生反应的概率似乎达到了收益递减点。高于此限度的血清浓度似乎既不会降低也不会增加产生反应的概率。